The 10-year is parked at 4.57%. Oil is moving higher. Tech is getting liquidated in a way that feels a little indiscriminate. And healthcare, which never gets credit until it does, is quietly absorbing capital that has nowhere else comfortable to go.

Seven names. Different reasons. Worth your time today.

QUALCOMM ($QCOM)

QCOM is trading around $203-$205 after a rough stretch. The stock dropped roughly 6-8% this week on ByteDance-building-custom-ASICs headlines, which rattled the broader semiconductor sector. The selling felt broader than the story warranted.

What people are conflating: Qualcomm is not a data center story. It is an edge AI story. Smartphones, automotive, IoT, the growing category of devices that need intelligence on-device rather than in a server rack somewhere. The QCT segment covers integrated circuits and system software for mobile and edge computing. That is structurally different from the server hardware names absorbing the brunt of export control risk right now. That distinction is getting lost.

FY2025 revenue came in at $44.28 billion, up 13.7% year over year. Last quarter: $2.65 EPS against a $2.56 estimate. JPMorgan raised its price target to $265 from $160 and put the stock on positive catalyst watch ahead of the June 24 investor day. Jensen Huang said something publicly supportive this week, which is worth at least a footnote. 52-week range is $121.99 to $259.92. Revenue growth projected at 10-12% for 2026. The argument for stepping in during the weakness is not that the AI trade is clean right now. It is that Qualcomm’s exposure is to device-level AI, which sits outside the blast radius of the server hardware export restrictions. The June 24 investor day will either confirm that or complicate it.

ELI LILLY ($LLY)

LLY closed around $1,144 Monday and has held near that level. The stock moved up roughly 4% earlier this week after Phase 3 data dropped at the American Diabetes Association’s 86th Scientific Sessions in New Orleans.

The data was not incremental. Retatrutide, the next-generation GIP/GLP-1/glucagon triple agonist, showed meaningful weight loss plus improvements in knee osteoarthritis pain, sleep apnea, and type 2 diabetes. Foundayo, the oral GLP-1 with no food or water restrictions, outperformed oral semaglutide on both A1C reduction and relative weight loss at 52 weeks in the ACHIEVE program. Management has guided for up to five approved obesity medicines by end of decade.

2025 revenue: $65.18 billion, up 44.7% year over year. Earnings grew 94.9%. Analyst consensus target around $1,215, Buy rating across 31 analysts.

Here is what matters in today’s specific context. GLP-1 demand does not respond to consumer sentiment surveys. It does not soften when gas prices climb or when confidence readings hit record lows. People who need Zepbound or Mounjaro still need them in any macro environment. That is not a growth argument. That is a stability argument. The revenue base here is insulated from the noise that is moving almost everything else today.

CISCO ($CSCO)

Cisco is trading around $119-$120, off its recent 52-week high of $130 after the broader tech selloff pulled it back modestly. The stock climbed roughly 87-93% over the past year on enterprise AI infrastructure demand and a pivot from pure hardware toward software and recurring subscription revenue. Bank of America raised its target to $135 with a Buy. JP Morgan maintains Buy. Consensus across 26 analysts is Buy, 12-month target around $126.50.

A slight tangent that is actually relevant here: Cisco climbed from roughly $77 in late March to $120+ in early June. That is a 54% move in one quarter. This is not a sleeper name anymore. It has moved. The question worth asking is whether the AI networking cycle has more room or whether 4.5%+ rates start to compress a multiple that has expanded considerably.

What Cisco Live 2026 showed: a unified Cloud Control AI platform, expanded cybersecurity offerings, and a deepened partnership with NetApp on AI-ready infrastructure. Routers, switches, cybersecurity, the Webex suite. Enterprise and government clients who do not cut infrastructure budgets when macro conditions get difficult. Dividend yield around 1.3%. Revenue recurring. The contrast with speculative chip names is clear right now, and that contrast is actively drawing capital.

EXXONMOBIL ($XOM)

XOM is trading around $148-$150. Brent spiked to $96.77 and WTI climbed to $93.48 this week after Iran suspended nuclear negotiations. The stock moved roughly 2.9% on those headlines and is holding near current levels.

The math behind this one is not complicated. The U.S.-Iran conflict has pushed crude from roughly $70 to the low-to-mid $90s since it escalated in late February. ExxonMobil’s upstream operations benefit directly when prices sustain at these levels. Q1 2026: $1.16 EPS against a $0.98 estimate, a 12.6% beat. Revenue hit $85.14 billion versus an $81.24 billion expectation. Record 2025 output near 4.7 million oil-equivalent barrels per day. Guyana at record production. Golden Pass LNG adding U.S. export capacity. Barclays has a target of $182 (Overweight). Mizuho revised higher after oil price adjustments. Broad analyst consensus Buy, 12-month target near $169.91. 52-week range $105.53 to $176.41.

The risk is also not complicated. XOM is a geopolitical proxy right now. A genuine ceasefire or diplomatic opening unwinds the war premium fast. This week demonstrated that clearly in both directions. As upstream energy, it is currently the most direct macro hedge available in equities for rising energy input costs. That comes with real headline exposure attached.

ORACLE ($ORCL) – Reports Tonight

Oracle reports Q4 FY2026 after the close today. The stock is around $206, having pulled back roughly 13% from recent highs despite a 42% surge since the March earnings call. The market has been patient. Tonight it wants something concrete.

What is interesting here is the scale of what Oracle is sitting on. A $553 billion remaining performance obligation backlog. Roughly eight times annual revenue. A substantial portion tied to a multi-year AI infrastructure agreement with OpenAI as part of the Stargate initiative. Cloud revenue grew 44% year over year to $8.9 billion in Q3. Management guided Q4 constant-currency revenue growth of 18-20%. Consensus estimate: approximately $19.1 billion in revenue and $1.96 EPS. TD Cowen raised its target to $300 from $250. The 10-year sitting at 4.57% is a real headwind for any high-multiple stock, but the backlog provides a level of multi-year revenue visibility that most growth companies cannot claim.

The EPS figure tonight matters less than the FY2027 guidance range and what management says about backlog conversion pace and data center capacity. The company secured 10 gigawatts of power for its pipeline over three years and added 400 MW in Q3 alone. The contracts exist. The question has always been whether they can build fast enough to monetize them on schedule. Tonight is when that answer starts to become clearer.

MASTERCARD ($MA)

MA is trading around $491. The 52-week high is $601.77. The 52-week low is $464.52. So the stock is closer to its floor than its ceiling right now, which is worth orienting around before anything else.

• Q1 2026: net revenue up 15.8% year over year
• Adjusted EPS up 23.3%
• Operating margin at 60.8%
• Value-added services up 22%
• 20 consecutive quarters of beating consensus
• 2025 revenue: $32.79 billion, up 16.4%

Strong Buy consensus across 39 analysts. 12-month target approximately $647, which implies roughly 32% from here.

What Mastercard actually is: a toll booth on global transaction volume. No credit risk on the books. Fees on every swipe, tap, and digital transfer across 200-plus countries in 150-plus currencies. When domestic purchasing power erodes, consumers shift spending internationally. Cross-border volume is where Mastercard’s fee economics are most favorable. Forward P/E around 23.9 is below the 10-year average. The company is also moving into stablecoins, agentic commerce, and real-time cross-currency infrastructure through its BVNK acquisition. Consumer sentiment at record lows is a real headline. But Mastercard earns on volume, not optimism. Those two things move independently of each other.

ZOETIS ($ZTS)

This one is not a clean story and it would be dishonest to frame it as one. ZTS dropped 21.5% on May 7 after Q1 2026 results came in with flat organic revenue growth, an EPS miss, and sharply reduced full-year guidance. Librela, the canine pain treatment that was supposed to be a major growth driver, has faced slowing veterinarian adoption after FDA safety warnings about neurological complications. Simparica Trio is losing market share to lower-cost competition. Argus downgraded to Hold. Shareholder lawsuits have been filed.

The stock is trading around $75-$79, down more than 50% from its 52-week high of $172.

What has not changed: Zoetis is still the world’s largest animal health company. More than 100 countries. Products spanning parasiticides, vaccines, dermatology, oncology, pain management, and diagnostics. The companion animal market does not respond to macro pressure the way discretionary consumer categories do. Pet owners treat sick animals regardless of what consumer confidence surveys say. And Zoetis has zero exposure to Medicare pricing negotiations, which have been a persistent source of headline risk for human pharmaceutical names.

Management guided 2%-5% organic revenue growth for 2026, with recovery weighted toward the second half. International surged 17% organically in Q1, which partially cushions the U.S. companion animal weakness. Next earnings August 11. Whether this is a value opportunity in a fundamentally sound business going through a product-cycle transition or a name that still has more unwinding to do is genuinely unclear. That is the honest read. Worth a look before the August report to decide which framing fits your risk tolerance.

For informational purposes only.